Yan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Zhang has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
Dana E. Selley
Virginia Commonwealth University 410 North 12th Street
43 shared publicationsWilliam L. Dewey
Virginia Commonwealth University 410 North 12th Street
29 shared publications- Piyusha P. Pagare
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, Virginia 23298, United States
24 shared publications David L. Stevens
Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, 410 North 12th Street, Richmond, Virginia23298, United States
19 shared publicationsHuiqun Wang
Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 East Leigh Street, Richmond, Virginia 23298, United States
18 shared publicationsYunyun Yuan
Department of Medicinal Chemistry, Virginia Commonwealth University, 800 East Leigh Street, P.O. Box 980540, Richmond, VA 23298, United States
17 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Design, Synthesis, and Pharmacological Characterization of Novel Kappa Opioid Receptor Agonists via Isosteric Replacement Strategy for Inflammatory Pain
Pain management remains a critical challenge, with mu opioid receptor (MOR) agonists carrying significant risks of respiratory depression and addiction. Kappa opioid receptor (KOR) agonists offer a promising alternative, but centrally mediated adverse effects such as sedation and dysphoria limit their clinical utility. We synthesized 24 nalfurafine analogues via isosteric replacement of its furan side chain with diverse aromatic moieties. All compounds retained high KOR binding affinity and full agonist efficacy, with most displaying G-protein biased signaling. Compound 10, prioritized based on its pharmacological profile, was inactive in thermal nociception assays at doses up to 10 mg/kg, yet produced potent, KOR-mediated antinociception in the acetic acid writhing assay (ED50 = 0.009 mg/kg) and attenuated colonic hypersensitivity in a TNBS-induced colitis model of chronic visceral pain, without significant hypolocomotion. Pharmacokinetic studies identified compound 10 as a P-glycoprotein substrate with limited brain exposure, consistent with a CNS-sparing profile and preferentially peripheral activity.
- 3 November 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Open AccessDesign, Synthesis, and Pharmacological Characterization of Novel Kappa Opioid Receptor Agonists via Isosteric Replacement Strategy for Inflammatory Pain
Pain management remains a critical challenge, with mu opioid receptor (MOR) agonists carrying significant risks of respiratory depression and addiction. Kappa opioid receptor (KOR) agonists offer a promising alternative, but centrally mediated adverse effects such as sedation and dysphoria limit their clinical utility. We synthesized 24 nalfurafine analogues via isosteric replacement of its furan side chain with diverse aromatic moieties. All compounds retained high KOR binding affinity and full agonist efficacy, with most displaying G-protein biased signaling. Compound 10, prioritized based on its pharmacological profile, was inactive in thermal nociception assays at doses up to 10 mg/kg, yet produced potent, KOR-mediated antinociception in the acetic acid writhing assay (ED50 = 0.009 mg/kg) and attenuated colonic hypersensitivity in a TNBS-induced colitis model of chronic visceral pain, without significant hypolocomotion. Pharmacokinetic studies identified compound 10 as a P-glycoprotein substrate with limited brain exposure, consistent with a CNS-sparing profile and preferentially peripheral activity.
- 23 October 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6) , 104840
Methadone: Historical success, modern challenges and lessons for opioid drug discovery
- 23 October 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6) , 104840
Methadone: Historical success, modern challenges and lessons for opioid drug discovery
- Open Access
- 6 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16658-16676
Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling
The surge in ultrapotent synthetic opioids has intensified the need for new chemical strategies for modulating the mu-opioid receptor (MOR). In this study, nitazene scaffold, a chemically distinct and underexplored chemotype, was utilized as an underexplored framework for MOR modulation. Structure-activity relationship studies were conducted through modifications at three key positions of the nitazene core and evaluated for MOR binding, in vitro functional, and in vivo behavioral activities. Among them, compound 26 significantly blocked the effects of synthetic opioids, including fentanyl and etonitazene. It also demonstrated affinity and selectivity for MOR and exhibited favorable metabolic stability and CNS permeability. Molecular modeling studies provided structural insights into potential binding modes of these ligands. This work expands the chemical space for opioid receptor ligands and provides a proof-of-concept that the nitazene core is chemically tunable for MOR functional modulation, highlighting nitazenes as a promising platform for future therapeutic exploration.
- 6 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16658-16676
Open AccessLandscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling
The surge in ultrapotent synthetic opioids has intensified the need for new chemical strategies for modulating the mu-opioid receptor (MOR). In this study, nitazene scaffold, a chemically distinct and underexplored chemotype, was utilized as an underexplored framework for MOR modulation. Structure-activity relationship studies were conducted through modifications at three key positions of the nitazene core and evaluated for MOR binding, in vitro functional, and in vivo behavioral activities. Among them, compound 26 significantly blocked the effects of synthetic opioids, including fentanyl and etonitazene. It also demonstrated affinity and selectivity for MOR and exhibited favorable metabolic stability and CNS permeability. Molecular modeling studies provided structural insights into potential binding modes of these ligands. This work expands the chemical space for opioid receptor ligands and provides a proof-of-concept that the nitazene core is chemically tunable for MOR functional modulation, highlighting nitazenes as a promising platform for future therapeutic exploration.
- Open Access
- 30 April 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (10) , 1888-1908
Structural Determinants of μ-Opioid Receptor Antagonism and Respiratory Liability in Phenylfentanyl Analogues
The μ-opioid receptor (MOR) plays a key role in opioid addiction and fentanyl-induced respiratory depression. Phenylfentanyl, previously reported as a MOR antagonist, paradoxically induces respiratory depression in vivo, revealing a dissociation between receptor antagonism and respiratory liability within this scaffold. To interrogate structural determinants underlying this activity profile, phenylfentanyl was redesigned through systematic modification of the acyl chain, N-alkyl group, and core ring scaffold, including exploration of a 6,6-ring extension to probe the MOR binding space. Seventy-eight compounds were synthesized and evaluated. The 6,6-ring series exhibited markedly reduced MOR activity relative to the 6-membered core analogues, likely due to suboptimal pharmacophore spacing. Among these, compound 5 demonstrated solid MOR antagonist activity, effectively blocking morphine- and fentanyl-induced antinociception in vivo and showing greater potency than phenylfentanyl in vitro. Importantly, compound 5 did not induce respiratory depression at the tested dose, indicating a lack of intrinsic respiratory liability. These findings delineate structural features governing MOR antagonism and respiratory effects within a fentanyl-derived scaffold.
- 30 April 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (10) , 1888-1908
Open AccessStructural Determinants of μ-Opioid Receptor Antagonism and Respiratory Liability in Phenylfentanyl Analogues
The μ-opioid receptor (MOR) plays a key role in opioid addiction and fentanyl-induced respiratory depression. Phenylfentanyl, previously reported as a MOR antagonist, paradoxically induces respiratory depression in vivo, revealing a dissociation between receptor antagonism and respiratory liability within this scaffold. To interrogate structural determinants underlying this activity profile, phenylfentanyl was redesigned through systematic modification of the acyl chain, N-alkyl group, and core ring scaffold, including exploration of a 6,6-ring extension to probe the MOR binding space. Seventy-eight compounds were synthesized and evaluated. The 6,6-ring series exhibited markedly reduced MOR activity relative to the 6-membered core analogues, likely due to suboptimal pharmacophore spacing. Among these, compound 5 demonstrated solid MOR antagonist activity, effectively blocking morphine- and fentanyl-induced antinociception in vivo and showing greater potency than phenylfentanyl in vitro. Importantly, compound 5 did not induce respiratory depression at the tested dose, indicating a lack of intrinsic respiratory liability. These findings delineate structural features governing MOR antagonism and respiratory effects within a fentanyl-derived scaffold.
- Open Access
- 22 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2330-2348
Investigating the Landscape of C6-Azaindole Side Chain on the Epoxymorphinan Skeleton via the Nitrogen Walk Concept: A Strategy to Enhance Drug-Like Properties
Opioid use disorder (OUD) affects 2.1 million people in the U.S., and current treatments have significant limitations. Therefore, there is a critical need for novel, selective, potent, and reversible mu opioid receptor (MOR) antagonists for OUD treatment. The "message-address" concept applied to the naltrexone skeleton keeps the epoxymorphinan core (message) consistent while modifying the C-6 substituent (address). This approach led to the development of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN). In this study, we have designed and evaluated NAN analogues to enhance their pharmacological properties by applying the "nitrogen-walk" concept, i.e., replacing each CH group with a nitrogen atom on the indole ring sequentially while exploring different attachment positions onto the azaindole ring. A total of 36 analogues were synthesized and characterized. Competitive binding assays and functional activity studies identified eight potential MOR antagonists, with compound 7 showing the highest potency in a mouse antinociception model and inducing fewer withdrawal symptoms than naloxone.
- 22 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2330-2348
Open AccessInvestigating the Landscape of C6-Azaindole Side Chain on the Epoxymorphinan Skeleton via the Nitrogen Walk Concept: A Strategy to Enhance Drug-Like Properties
Opioid use disorder (OUD) affects 2.1 million people in the U.S., and current treatments have significant limitations. Therefore, there is a critical need for novel, selective, potent, and reversible mu opioid receptor (MOR) antagonists for OUD treatment. The "message-address" concept applied to the naltrexone skeleton keeps the epoxymorphinan core (message) consistent while modifying the C-6 substituent (address). This approach led to the development of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN). In this study, we have designed and evaluated NAN analogues to enhance their pharmacological properties by applying the "nitrogen-walk" concept, i.e., replacing each CH group with a nitrogen atom on the indole ring sequentially while exploring different attachment positions onto the azaindole ring. A total of 36 analogues were synthesized and characterized. Competitive binding assays and functional activity studies identified eight potential MOR antagonists, with compound 7 showing the highest potency in a mouse antinociception model and inducing fewer withdrawal symptoms than naloxone.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Development of novel Mu opioid receptor antagonists based on a 6,4-spiro bicyclic fentanyl-derived scaffold
Scaffold reorganization represents a strategy for modulating Mu opioid receptor (MOR) signaling within flexible opioid scaffolds.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Open AccessDevelopment of novel Mu opioid receptor antagonists based on a 6,4-spiro bicyclic fentanyl-derived scaffold
Scaffold reorganization represents a strategy for modulating Mu opioid receptor (MOR) signaling within flexible opioid scaffolds.
- 27 November 2025
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 150, 110206
Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes
- 27 November 2025
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 150, 110206
Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes
- Open Access
- 3 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 22170-22195
Design, Syntheses, and Pharmacological Evaluations of Core Ring Expanded Fentanyl Analogues as Potential Counteracting Agents Against Fentanyl Induced Respiratory Depression
The escalating synthetic opioid crisis necessitates novel treatments, especially for fentanyl overdose. This study presents 84 ring-expanded fentanyl analogs, replacing its piperidine core with 4-azepane and 5-azocane structures. In vivo antagonism studies identified 15 compounds that effectively blocked synthetic opioid antinociception. Further dose-response analysis identified four potent antagonists (16, 46, 53, and 69) against both fentanyl and morphine. Notably, Compound 53 demonstrated the highest potency with AD50 of 2.02 mg/kg against morphine and 4.02 mg/kg against fentanyl. Compound 53 exhibits a favorable pharmacokinetic profile, including moderate human metabolic stability, low efflux, and efficient, sustained CNS penetration, making it a promising centrally acting MOR antagonist candidate. Significantly, whole-body plethysmography confirmed that compound 53 reversed fentanyl-induced respiratory depression. These results suggest that expanding the core ring structure of fentanyl is a promising strategy to develop potent mu opioid receptor antagonists to inhibit both antinociception and respiratory depression offering potential solutions to fentanyl overdose.
- 3 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 22170-22195
Open AccessDesign, Syntheses, and Pharmacological Evaluations of Core Ring Expanded Fentanyl Analogues as Potential Counteracting Agents Against Fentanyl Induced Respiratory Depression
The escalating synthetic opioid crisis necessitates novel treatments, especially for fentanyl overdose. This study presents 84 ring-expanded fentanyl analogs, replacing its piperidine core with 4-azepane and 5-azocane structures. In vivo antagonism studies identified 15 compounds that effectively blocked synthetic opioid antinociception. Further dose-response analysis identified four potent antagonists (16, 46, 53, and 69) against both fentanyl and morphine. Notably, Compound 53 demonstrated the highest potency with AD50 of 2.02 mg/kg against morphine and 4.02 mg/kg against fentanyl. Compound 53 exhibits a favorable pharmacokinetic profile, including moderate human metabolic stability, low efflux, and efficient, sustained CNS penetration, making it a promising centrally acting MOR antagonist candidate. Significantly, whole-body plethysmography confirmed that compound 53 reversed fentanyl-induced respiratory depression. These results suggest that expanding the core ring structure of fentanyl is a promising strategy to develop potent mu opioid receptor antagonists to inhibit both antinociception and respiratory depression offering potential solutions to fentanyl overdose.
- Open Access
- 5 May 2025
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 6 (7) , 1115-1125
Exploring substitution effects on the potential dominant conformations of NBF derivatives leading to functional conversion at the mu opioid receptor
The structure–activity relationship studies on NBF provide insights for functional conversions at the mu opioid receptor and support future endeavors in developing novel and selective opioid ligands.
- 5 May 2025
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 6 (7) , 1115-1125
Open AccessExploring substitution effects on the potential dominant conformations of NBF derivatives leading to functional conversion at the mu opioid receptor
The structure–activity relationship studies on NBF provide insights for functional conversions at the mu opioid receptor and support future endeavors in developing novel and selective opioid ligands.
- Open Access
- 5 December 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (12) , 4165-4182
Discovery of 6α-Thiazolylcarboxamidonaltrexamine Derivative (NTZ) as a Potent and Central Nervous System Penetrant Opioid Receptor Modulator with Drug-like Properties for Potential Treatment of Opioid Use Disorder
The development of highly potent and selective μ opioid receptor (MOR) modulators with favorable drug-like properties has always been a focus in the opioid domain. Our previous efforts led to the discovery of a lead compound designated as NAT, a potent centrally acting MOR modulator. However, the fact that NAT precipitated considerable withdrawal effects at higher doses largely impaired its further development. In the light of the concept of activity cliff and CNS multiparameter optimization algorithm, a nitrogen atom was incorporated into the thiophene ring of NAT, aiming to preserve desirable pharmacological activities and CNS permeability while alleviating withdrawal symptoms. Among all 16 new analogs, compound 6 (NTZ) exhibited improved opioid receptor selectivity, enhanced in vivo antagonistic effect, and overall fewer withdrawal symptoms compared to NAT. Further assessment of several key drug-like properties suggested a favorable ADMET profile of NTZ. Taken together, NTZ shows promise as a potential lead to treat opioid use disorder.
- 5 December 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (12) , 4165-4182
Open AccessDiscovery of 6α-Thiazolylcarboxamidonaltrexamine Derivative (NTZ) as a Potent and Central Nervous System Penetrant Opioid Receptor Modulator with Drug-like Properties for Potential Treatment of Opioid Use Disorder
The development of highly potent and selective μ opioid receptor (MOR) modulators with favorable drug-like properties has always been a focus in the opioid domain. Our previous efforts led to the discovery of a lead compound designated as NAT, a potent centrally acting MOR modulator. However, the fact that NAT precipitated considerable withdrawal effects at higher doses largely impaired its further development. In the light of the concept of activity cliff and CNS multiparameter optimization algorithm, a nitrogen atom was incorporated into the thiophene ring of NAT, aiming to preserve desirable pharmacological activities and CNS permeability while alleviating withdrawal symptoms. Among all 16 new analogs, compound 6 (NTZ) exhibited improved opioid receptor selectivity, enhanced in vivo antagonistic effect, and overall fewer withdrawal symptoms compared to NAT. Further assessment of several key drug-like properties suggested a favorable ADMET profile of NTZ. Taken together, NTZ shows promise as a potential lead to treat opioid use disorder.